
Opinion|Videos|October 3, 2024
Emerging Trends in Chronic GVHD: Promising Clinical Trials and the Future Treatment Landscape
Medical experts discuss emerging trends in chronic GVHD treatment.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Which ongoing clinical trials for cGVHD and prophylaxis are you excited about?
- How do you expect the cGVHD treatment landscape to change in the next couple of years?
- How do you keep informed of updates at major medical congresses?
Advertisement
Related to this article

Jorge Cortes, MD, discusses response-based ponatinib dosing, mutation testing, and managing cardiovascular risk in resistant CML.

The EC approved every-6-week maintenance dosing and shorter 350-mg infusions for cemiplimab across all 6 EU indications.

Faculty convened at an OncLive Scientific Interchange and Workshop to guide oncology fellows through designing a cancer clinical trial development program, from concept to approval.

The FDA granted priority review to sonesitatug vedotin for previously treated CLDN18.2-positive advanced gastroesophageal cancers.

UCLA Health performs its first single-port robotic lobectomy, using a new technique that could reduce pain and make recovery easier for patients with lung cancer.

Narek Shaverdian, MD, outlines how novel strategies may reshape unresectable stage III NSCLC management.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Priority Review to Sonesitatug Vedotin in CLDN18.2+ Gastroesophageal Cancer
2
EC Approves Extended Cemiplimab Dosing in Skin, Lung, and Cervical Cancers
3
Dose Optimization, Evidentiary Bars, and Patient Selection Shape Trial Design in EGFR- and HER2-Mutant NSCLC
4
Defining High-Risk Localized Prostate Cancer and the DASL-HiCaP Trial
5


